Treatment Paradigms for Clinical Progression of CLL/SLL Beyond Initial Therapies
An expert on CLL/SLL provides clinical insights on approaching the treatment of patients who progress beyond initial therapy.
EP: 1.Clinical Approaches in High-Risk Patients with CLL/SLL
EP: 2.SEQUOIA Arm D Study: Zanubrutinib plus Venetoclax in Treatment-Naive CLL/SLL with del(17p) and/or TP53 Mutations
EP: 3.Updates from the CAPTIVATE Study Evaluating Ibrutinib + Venetoclax in TN CLL/SLL
EP: 4.Future Implications of Combination Regimens and Treatment Duration in CLL/SLL
EP: 5.Examining Toxicity Management of BTK Inhibitors for CLL/SLL
EP: 6.Treatment Paradigms for Clinical Progression of CLL/SLL Beyond Initial Therapies
EP: 7.Perspectives on Indirect Comparisons of BTK Inhibitors for R/R CLL/SLL
EP: 8.Additional Data and Key Takeaways in CLL/SLL from EHA 2024
EP: 9.Future Outlooks in the Treatment of CLL/SLL
Video content above is prompted by the following questions:
- How do you approach treatment for patients that progress beyond initial therapy in CLL/SLL?
- What factors influence the choice of retreatment options after prior BTK inhibitor therapy?
- What factors influence the choice of retreatment options after prior BTK inhibitor therapy?
In CLL/SLL, Zanubrutinib Linked to Lower Switch Rates vs Other BTK Inhibitors
September 12th 2024Findings from a real-world study showed that zanubrutinib was associated with lower rates of treatment switching and patients receiving subsequent therapy compared with acalabrutinib and ibrutinib in patients with CLL or SLL.
Read More
One Arm of SEQUOIA Trial Shows 100% Response in High-Risk CLL/SLL
August 15th 2024Zanubrutinib with venetoclax led to an overall response rate of 100% when used for treating patients with treatment-naive chronic lymphocytic leukemia or small lymphocytic lymphoma with 17p deletions and/or TP53 mutations.
Read More
